Global Acute Myeloid Leukaemia Therapeutics Market Research Report 2024(Status and Outlook)

Global Acute Myeloid Leukaemia Therapeutics Market Research Report 2024(Status and Outlook)



Report Overview:

The Global Acute Myeloid Leukaemia Therapeutics Market Size was estimated at USD 3882.64 million in 2023 and is projected to reach USD 7145.17 million by 2029, exhibiting a CAGR of 10.70% during the forecast period.

This report provides a deep insight into the global Acute Myeloid Leukaemia Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Acute Myeloid Leukaemia Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Acute Myeloid Leukaemia Therapeutics market in any manner.

Global Acute Myeloid Leukaemia Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Pfizer Inc.

Novartis AG

Celgene Corporation

Astellas Pharma Inc.

Daiichi Sankyo Company, Limited

Jazz Pharmaceuticals

Boehringer Ingelheim International GmbH

Johnson & Johnson

Gilead Sciences, Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Sunesis Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Market Segmentation (by Type)

Chemotherapy

Targeted Therapy

Immunotherapy

Hypomethylating Agents

Others

Market Segmentation (by Application)

Specialty Clinics

Hospital

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Acute Myeloid Leukaemia Therapeutics Market

Overview of the regional outlook of the Acute Myeloid Leukaemia Therapeutics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Acute Myeloid Leukaemia Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Acute Myeloid Leukaemia Therapeutics
1.2 Key Market Segments
1.2.1 Acute Myeloid Leukaemia Therapeutics Segment by Type
1.2.2 Acute Myeloid Leukaemia Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Acute Myeloid Leukaemia Therapeutics Market Overview
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Acute Myeloid Leukaemia Therapeutics Market Competitive Landscape
3.1 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Company (2019-2024)
3.2 Acute Myeloid Leukaemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Acute Myeloid Leukaemia Therapeutics Market Size Sites, Area Served, Product Type
3.4 Acute Myeloid Leukaemia Therapeutics Market Competitive Situation and Trends
3.4.1 Acute Myeloid Leukaemia Therapeutics Market Concentration Rate
3.4.2 Global 5 and 10 Largest Acute Myeloid Leukaemia Therapeutics Players Market Share by Revenue
3.4.3 Mergers & Acquisitions, Expansion
4 Acute Myeloid Leukaemia Therapeutics Value Chain Analysis
4.1 Acute Myeloid Leukaemia Therapeutics Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 The Development and Dynamics of Acute Myeloid Leukaemia Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 Mergers & Acquisitions
5.5.2 Expansions
5.5.3 Collaboration/Supply Contracts
5.6 Industry Policies
6 Acute Myeloid Leukaemia Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Type (2019-2024)
6.3 Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Type (2019-2024)
7 Acute Myeloid Leukaemia Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Acute Myeloid Leukaemia Therapeutics Market Size (M USD) by Application (2019-2024)
7.3 Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Application (2019-2024)
8 Acute Myeloid Leukaemia Therapeutics Market Segmentation by Region
8.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region
8.1.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region
8.1.2 Global Acute Myeloid Leukaemia Therapeutics Market Size Market Share by Region
8.2 North America
8.2.1 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Pfizer Inc.
9.1.1 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.1.2 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics SWOT Analysis
9.1.5 Pfizer Inc. Business Overview
9.1.6 Pfizer Inc. Recent Developments
9.2 Novartis AG
9.2.1 Novartis AG Acute Myeloid Leukaemia Therapeutics Basic Information
9.2.2 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Overview
9.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.2.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics SWOT Analysis
9.2.5 Novartis AG Business Overview
9.2.6 Novartis AG Recent Developments
9.3 Celgene Corporation
9.3.1 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Basic Information
9.3.2 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Overview
9.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.3.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics SWOT Analysis
9.3.5 Celgene Corporation Business Overview
9.3.6 Celgene Corporation Recent Developments
9.4 Astellas Pharma Inc.
9.4.1 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.4.2 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.4.4 Astellas Pharma Inc. Business Overview
9.4.5 Astellas Pharma Inc. Recent Developments
9.5 Daiichi Sankyo Company, Limited
9.5.1 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Basic Information
9.5.2 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Overview
9.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.5.4 Daiichi Sankyo Company, Limited Business Overview
9.5.5 Daiichi Sankyo Company, Limited Recent Developments
9.6 Jazz Pharmaceuticals
9.6.1 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Basic Information
9.6.2 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Overview
9.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.6.4 Jazz Pharmaceuticals Business Overview
9.6.5 Jazz Pharmaceuticals Recent Developments
9.7 Boehringer Ingelheim International GmbH
9.7.1 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Basic Information
9.7.2 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Overview
9.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.7.4 Boehringer Ingelheim International GmbH Business Overview
9.7.5 Boehringer Ingelheim International GmbH Recent Developments
9.8 Johnson and Johnson
9.8.1 Johnson and Johnson Acute Myeloid Leukaemia Therapeutics Basic Information
9.8.2 Johnson and Johnson Acute Myeloid Leukaemia Therapeutics Product Overview
9.8.3 Johnson and Johnson Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.8.4 Johnson and Johnson Business Overview
9.8.5 Johnson and Johnson Recent Developments
9.9 Gilead Sciences, Inc.
9.9.1 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.9.2 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.9.4 Gilead Sciences, Inc. Business Overview
9.9.5 Gilead Sciences, Inc. Recent Developments
9.10 Amgen Inc.
9.10.1 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.10.2 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.10.4 Amgen Inc. Business Overview
9.10.5 Amgen Inc. Recent Developments
9.11 Takeda Pharmaceutical Company Limited
9.11.1 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Basic Information
9.11.2 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Overview
9.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.11.4 Takeda Pharmaceutical Company Limited Business Overview
9.11.5 Takeda Pharmaceutical Company Limited Recent Developments
9.12 Sunesis Pharmaceuticals, Inc.
9.12.1 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.12.2 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.12.4 Sunesis Pharmaceuticals, Inc. Business Overview
9.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments
9.13 Agios Pharmaceuticals, Inc.
9.13.1 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Basic Information
9.13.2 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Overview
9.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Market Performance
9.13.4 Agios Pharmaceuticals, Inc. Business Overview
9.13.5 Agios Pharmaceuticals, Inc. Recent Developments
10 Acute Myeloid Leukaemia Therapeutics Regional Market Forecast
10.1 Global Acute Myeloid Leukaemia Therapeutics Market Size Forecast
10.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Region
10.2.4 South America Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Acute Myeloid Leukaemia Therapeutics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Type (2025-2030)
11.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings